173 related articles for article (PubMed ID: 31474587)
1. A proposal for a new classification of "unfavorable risk criteria" in patients with stage I endometrial cancer.
Li R; Shinde A; Han E; Lee S; Beriwal S; Harkenrider M; Kamrava M; Chen YJ; Glaser S
Int J Gynecol Cancer; 2019 Sep; 29(7):1086-1093. PubMed ID: 31474587
[TBL] [Abstract][Full Text] [Related]
2. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
[TBL] [Abstract][Full Text] [Related]
4. Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular Classification.
Zammarrelli WA; Kim SH; Da Cruz Paula A; Rios-Doria EV; Ehmann S; Yeoshoua E; Hanlon EJ; Zhou Q; Iasonos A; Alektiar KM; Aghajanian C; Makker V; Leitao MM; Abu-Rustum NR; Ellenson LH; Weigelt B; Mueller JJ
JCO Precis Oncol; 2022 Oct; 6():e2200194. PubMed ID: 36240474
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation.
McCloskey SA; Tchabo NE; Malhotra HK; Odunsi K; Rodabaugh K; Singhal P; Lele S; Jaggernauth W
Gynecol Oncol; 2010 Mar; 116(3):404-7. PubMed ID: 19944453
[TBL] [Abstract][Full Text] [Related]
6. The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer.
Chino JP; Jones E; Berchuck A; Secord AA; Havrilesky LJ
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1872-9. PubMed ID: 21640502
[TBL] [Abstract][Full Text] [Related]
7. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.
Bosse T; Nout RA; Stelloo E; Dreef E; Nijman HW; Jürgenliemk-Schulz IM; Jobsen JJ; Creutzberg CL; Smit VT
Eur J Cancer; 2014 Oct; 50(15):2602-10. PubMed ID: 25126672
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant radiation therapy is associated with improved overall survival in high-intermediate risk stage I endometrial cancer: A national cancer data base analysis.
Gupta V; McGunigal M; Prasad-Hayes M; Kalir T; Liu J
Gynecol Oncol; 2017 Jan; 144(1):119-124. PubMed ID: 27793358
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant radiation in early stage, unfavorable histology endometrial carcinoma is associated with improved local control and survival.
Ly D; Rowley BD; Dodson MK; Soisson PA; Jolles CJ; Gaffney DK; Sause WT
Gynecol Oncol; 2014 May; 133(2):250-5. PubMed ID: 24589416
[TBL] [Abstract][Full Text] [Related]
10. Patterns of adjuvant radiation usage and survival outcomes for stage I endometrial carcinoma in a large hospital-based cohort.
Wong AT; Rineer J; Schwartz D; Weiner J; Safdieh J; Choi K; Schreiber D
Gynecol Oncol; 2017 Jan; 144(1):113-118. PubMed ID: 27823769
[TBL] [Abstract][Full Text] [Related]
11. Single-institutional outcomes of adjuvant brachytherapy for Stage I endometrial cancer-Are outcomes consistent with randomized studies?
Dohopolski MJ; Horne ZD; Gebhardt BJ; Glaser SM; Edwards RP; Kelley JL; Comerci JT; Olawaiye AB; Courtney-Brooks M; Berger JL; Sukumvanich P; Beriwal S
Brachytherapy; 2018; 17(3):564-570. PubMed ID: 29426745
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of outcomes of endometrial cancer patients included in prospective clinical trials.
Boone RM; Praiss AM; Huang Y; Melamed A; Khoury-Collado F; Hou JY; Gockley A; St Clair CM; Hershman DL; Wright JD
Gynecol Oncol; 2023 Feb; 169():70-77. PubMed ID: 36521351
[TBL] [Abstract][Full Text] [Related]
13. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials.
Creutzberg CL; van Stiphout RG; Nout RA; Lutgens LC; Jürgenliemk-Schulz IM; Jobsen JJ; Smit VT; Lambin P
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):530-9. PubMed ID: 25680597
[TBL] [Abstract][Full Text] [Related]
14. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant radiation therapy is associated with improved pelvic control and overall survival in FIGO IB endometrial carcinoma with high grade histology.
Ly D; Soisson PA; Dodson MK; Sause WT; Gaffney DK
Gynecol Oncol; 2015 Sep; 138(3):526-31. PubMed ID: 26095895
[TBL] [Abstract][Full Text] [Related]
16. Improved overall survival with adjuvant radiotherapy for high-intermediate and high risk Stage I endometrial cancer.
Harkenrider MM; Adams W; Block AM; Kliethermes S; Small W; Grover S
Radiother Oncol; 2017 Mar; 122(3):452-457. PubMed ID: 28012794
[TBL] [Abstract][Full Text] [Related]
17. Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer: a validation study of the Gynecologic Oncology Group criteria.
Kong TW; Chang SJ; Paek J; Lee Y; Chun M; Ryu HS
J Gynecol Oncol; 2015 Jan; 26(1):32-9. PubMed ID: 25376915
[TBL] [Abstract][Full Text] [Related]
18. Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2.
Bishop EA; Java JJ; Moore KN; Walker JL
Int J Gynecol Cancer; 2017 May; 27(4):730-737. PubMed ID: 28399028
[TBL] [Abstract][Full Text] [Related]
19. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy in patients with clear cell endometrial carcinoma: An analysis of the National Cancer Database.
Nieto K; Adams W; Pham N; Block AM; Grover S; Small W; Harkenrider MM
Gynecol Oncol; 2018 Jan; 148(1):147-153. PubMed ID: 29129389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
